BCE Bell notches 79 percent Q4 2025 EPS beat but shares dip 091 percent in todays trading AbbVie Inc ABBV Submits SKYRIZI Subcutaneous Crohns Regimen to FDA But NearTerm Upside Remains Capped By Competitive Risks Cognex CGNX Stock Working Order Marginal Gain 20260427